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Background: People with vascular risk factors are at increased risk for cognitive impairment 
as well as vascular disease. The objective of this study was to evaluate whether vascular risk 
factor clinical practice guidelines consider cognition as an outcome or in connection with 
treatment compliance.
Methods: Articles from PubMed, EMBASE, and the Cochrane Library were assessed by at 
least two reviewers and were included if: (1) Either hypertension, high cholesterol, diabetes, or 
atrial fibrillation was targeted; (2) The guideline was directed at physicians; (3) Adult patients 
(aged 19 years or older) were targeted; and (4) The guideline was published in English. Of 91 
guidelines, most were excluded because they were duplicates, older versions, or focused on 
single outcomes.
Results: Of the 20 clinical practice guidelines that met inclusion criteria, five mentioned 
cognition. Of these five, four described potential treatment benefits but only two mentioned 
that cognition may affect compliance. No guidelines adequately described how to screen for 
cognitive impairment.
Conclusion: Despite evidence that links cognitive impairment to vascular risk factors, only 
a minority of clinical practice guidelines for the treatment of vascular risk factors consider 
cognition as either an adverse outcome or as a factor to consider in treatment.
Keywords: clinical practice guidelines, evidence-based medicine, vascular risk, cognition, 
target organ damage
As people age, they are more susceptible to dementia and as populations age, the 
dementias generally become more common.1,2 These particularly burdensome illnesses 
have important public health consequences.2,3 As a result, new effort has focused on 
whether dementia is preventable, and in particular whether vascular risk factor control 
might yield this additional benefit.4,5
The idea that vascular risk factor control might prevent dementia is not new. Our 
understanding of the relationship between vascular risk factors and dementia evolved 
from the ancient view that Alzheimer’s disease arose from ‘hardening of the arteries.’ 
That idea gave way in the 1970s to a hard-won conceptual distinction between 
neurodegenerative dementias on the one hand and dementias from vascular causes 
on the other.6 Later, we came again to understand that the two are related,7 as it was 
appreciated that vascular risk factors are not only important for vascular dementias 
but are also risk factors for Alzheimer’s disease.8 Neuropathological studies indicate 
that cerebrovascular pathology and neurodegenerative pathology uncommonly appear Clinical Interventions in Aging 2009:4 426
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in isolation in elderly people,9,10 and that they can have 
synergistic effect on cognitive impairment,11,12 although this 
need not always be the case.13,14 In addition, dementia and 
atherosclerosis share both risk factors (hypertension, elevated 
cholesterol, diabetes) and pathologic features (inflammatory 
markers, protein mis-folding).15
Given the importance now accorded to vascular risk factors 
in dementia, there is new interest in whether the treatment of 
vascular risk factors might reduce or prevent the incidence of 
dementia. Of note, treatment of hypertension, both in midlife 
and in old age, appears to reduce the risk of cognitive impair-
ment in later life.16–19 Statin therapy is also associated with 
a reduced cognitive decline in patients with elevated serum 
cholesterol, although this relationship has been inconsistent.20 
Physical activity and a mediterranean diet, often advocated to 
lessen risk of vascular disease, are also associated with a reduced 
risk of dementia and cognitive decline.21–24 In consequence, the 
treatment of vascular risk factors prescribed to prevent outcomes 
such as myocardial infarction or renal insufficiency may also 
prevent adverse cognitive outcomes, although whether this 
should be a matter of public health policy is debated.3,4
Against this background, it seems reasonable that clinical 
practice guidelines for the treatment of vascular risk factors 
should include cognition as an aspect of target organ damage, 
even if prevention of damage is not always be possible. Our 
cursory impression was that this is not the case. In conse-
quence, we investigated the extent to which cognition is 
included as an aspect of end-organ damage in clinical practice 
guidelines for the treatment for vascular risk factors. We 
considered cognition in the context of other attributes of the 




PubMed, EMBASE, and the Cochrane Library were searched 
for items published between January 1st, 2001 and August 
30th, 2008.
Review methods
Search terms included the medical subject headings 
hypertension, diabetes mellitus, diabetes mellitus – type 2, 
hypercholesterolemia, hypercholesterolemia – familial, and 
atrial fibrillation.
Inclusion criteria
Articles were included if they met the following criteria: 
1. Hypertension, high cholesterol, diabetes, and/or atrial 
fibrillation was targeted; 2. The guideline was directed at 
physicians; 3. Adult patients (aged 19 years or older) were 
targeted; and 4. The guideline was published in English. 
In the case of duplicated or updated guidelines, only the most 
recent clinical practice guideline from a given organization 
or group of authors was considered. Only the unabridged 
versions of duplicated guidelines were reviewed.
Studies were independently evaluated for inclusion by two 
reviewers. Where disagreement arose, a third reviewer came 
to a resolution. We performed an independent assessment of 
both the processes by which guidelines were developed and 
their content with respect to the assessment of end-organ 
damage. To evaluate the process, a quality assessment 
instrument (Supplementary Material A) was developed, 
based on a more general instrument for evaluating the 
quality of consensus guidelines.25 Here, we also noted the 
composition of the review teams and specifically whether they 
included physicians likely to have an interest in cognition. 
To evaluate the content, we developed another standardized 
assessment (Supplementary Material B). We evaluated how 
commonly cognition was mentioned and how frequently 
it was mentioned in comparison with other outcomes. 
In addition to renal disease and claudication, pheochromo-
cytoma was included to compare the inclusion of cognition 
to another disorder that is much less common than cognitive 
impairment but which is traditionally considered in people 
with hypertension.
Results
The initial database search revealed 321 articles for further 
consideration of which only 91 were clinical practice 
guidelines. Once guidelines that were targeted to nonadult 
populations, not aimed at physicians, focused on few or 
only one specific outcomes, or were joint/older versions of 
publications were eliminated, 20 relevant clinical practice 
guidelines remained (Table 1).26–45
Of the 20 clinical practice guidelines that met all criteria, 
five mentioned cognition. Of these five, four discussed 
cognition as an aspect of target organ damage and 
suggested that cognition may benefit from treatment. Two 
discussed cognitive impairment with respect to treatment 
compliance but no guideline thoroughly discussed the 
assessment of cognition. Of the guidelines that mentioned 
cognition, four focused on hypertension and one targeted 
diabetes.
Guidelines that mentioned cognitive impairment as an 
outcome of uncontrolled vascular risk factors were more 
likely to have mentioned claudication and renal function. Clinical Interventions in Aging 2009:4 427
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A larger portion of the guidelines that mentioned cognition 
also included descriptive studies in the evidence and provided 
a description of the authors. Studies that cited cognition were 
also less likely to describe the search strategy and explicitly 
link evidence to the strength of the guidelines (Table 2).
Discussion
The number of people diagnosed with dementia is expected to 
surge in the upcoming decades largely because of more people 
living to an age where dementia is common.1,2 As a result, the 
prevention of dementia has emerged as a major public health 
focus46 and vascular risk factor control is one of the most 
promising factors for the prevention of dementia.47 Despite 
the strong association between vascular risk factors and 
dementia, this review of current clinical practice guidelines 
for vascular risk factor management indicated that only a 
minority (four of 20) discussed cognition either as an aspect 
of target organ damage or as a consideration in treatment. The 
mention of cognition tended to be idiosyncratic, and unrelated 
to most other measures of the completeness of the guidelines 
or to the processes by which they were achieved.
Our data must be interpreted with caution. Language bias 
could be present because only guidelines published in Eng-
lish were included. However, a guideline from South Africa 
was included along with guidelines from North America and 
Europe and a systematic strategy was followed. In addition, 
our search ended prior to the publication of the Hypertension 
in the Very Elderly Trial data and its analyses of the impact 
of hypertension treatment on cognition.18 While the study 
was not entirely conclusive, the results favored hypertension 
Table 1 Characteristics of clinical practice guidelines included in the review
Association Year Vascular risk factor Target population
American College of Chest Physicians36 2004 Atrial fibrillation Not specified
American Academy of Family Physicians, 
American College of Physicians38
2003 Atrial fibrillation: First-
detected
Adults with first-detected 
atrial fibrillation
American College of Cardiology,   American 
heart   Association, european society of 
Cardiology37
2001 Atrial fibrillation Not specified
California healthcare Foundation,   American 
geriatrics society26
2003 Diabetes Older persons
Us Preventive services Task Force41 2003 Diabetes: diabetes 
mellitus
Adults (diabetes mellitus)
Agencé nationale d’Accréditation et 
d’Évaluation en santé28
2000 Diabetes: type 2 diabetes Type 2 diabetics without 
complications
Canadian Cardiovascular society42 2006 Cholesterol: dyslipidemia
American Diabetes   Association23 2004 Cholesterol: dyslipidemia Adults with diabetes
national Cholesterol education Program30 2002 Cholesterol: high blood 
cholesterol
Adults
American Diabetes   Association24 2004 hypertension Adults with diabetes
American hypertension   Association33 2008 hypertension Adults
Canadian hypertension education Program29 2007 hypertension therapy Adults
Canadian hypertension education Program32 2007 hypertension: diagnosis 
and risk
Adults
european society of hypertension39 2007 hypertension: arterial Not specified
Joint National Committee-727 2003 hypertension: high 
blood pressure
Not specified
national Collaborating Centre for Chronic 
Conditions31
2006 hypertension Not specified
south   African hypertension society34 2006 hypertension Adults
Us Preventative services   Task Force40 2003 hypertension: high 
blood pressure
Adults
Agencé nationale d’Accréditation 
et d’Évaluation en santé25
2005 hypertension Adults
American geriatrics society35 2001 Anticoagulants  
(Warfarin)
Older peopleClinical Interventions in Aging 2009:4 428
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treatment for the benefit of cognition when combined into a 
meta-analysis.18 Future clinical practice guidelines targeting 
hypertension may include cognition in consequence to these 
results.
There is substantial evidence to suggest that people 
who have vascular risk factors are at elevated risk for 
cognitive impairment.15 In addition, there is preliminary 
evidence to suggest that lifestyle modification through 
diet and exercise and the treatment of vascular risk 
factors, particularly hypertension, may partially reduce 
this risk.16–19,23,24 Even so, our study found that few guide-
lines for vascular risk factors mention cognition and even 
fewer make clear recommendations for the screening and 
evaluation of cognitive impairment as an adverse outcome 
of vascular risk factors. As a result, physicians are likely 
to underestimate the cognitive impact of vascular disease. 
Even stroke neurologists have been urged to better recog-
nize cognitive impairment in patients with cerebrovascular 
disease.48
Review procedures that emphasize randomized control 
trials and downgrade evidence from epidemiological stud-
ies often overlook the weaknesses of these trials, such as 
poor validity to clinical populations. In particular, stroke 
guidelines have been criticized for being derived from 
study populations that do not adequately reflect those seen 
in primary care.49 If the outcomes that are important for 
inclusion in clinical practice guidelines are those that most 
impact patients’ lives and well-being, as has been suggested,30 
then cognition is of utmost importance even if the treatment 
evidence is primarily observational and preliminary in 
controlled trials.16–20 That some guidelines described the 
evaluation of pheochromocytoma, but not cognition, suggests 
that the population burden of illness has not always been 
considered of primary importance when developing vascular 
risk factor guidelines.
Dementia guidelines indicate that people with hyper-
tension, hyperlipidemia, and diabetes are at high risk for 
dementia and indicate that for hypertension, treatment will 
reduce this risk.50,51 It follows that clinical practice guidelines 
for the management of vascular risk factors, and particularly 
hypertension, should similarly recommend that practitioners 
consider patients with vascular risk factors to be at high risk 
for cognitive impairment, particularly with patients who 
are at an age (65 years) where cognitive impairment is 
common. Cognitive screening by general practitioners, cardi-
ologists and other physicians has the potential to detect more 
patients in the earliest stages of cognitive impairment and 
dementia, where early detection is important for treatment 
Table 2 A comparison of the vascular risk factor clinical practice guidelines that mentioned cognition (n = 5) to those that did not (n = 15)
Questions Answer Mentioned cognition?
    Yes No

































































13Clinical Interventions in Aging 2009:4 429
Vascular risk factor guidelines and cognition Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
and will become increasingly important as more preventative 
therapies are identified.52
Magnetic resonance imaging (MRI) can provide a detailed 
image of the brain and cerebrovascular system. However, 
the structural changes detected with MRI do not accurately 
predict the clinical manifestation53 of cognitive impairment 
so cognitive testing is imperative. With the development of 
new cognitive testing guidelines,48 which include a 30 minute 
and a 5–10 minute standardized cognitive battery, it is now 
relatively straightforward to administer cognitive testing that 
is more sensitive to vascular cognitive impairment than the 
traditionally used Mini-Mental State Examination (MMSE),54 
which is relatively insensitive to the executive dysfunction 
and subtle memory changes that are important to the 
diagnosis of vascular cognitive impairment.55 Since the five-
minute battery can be administered by study personnel with 
minimal training, including a version that can be administered 
by telephone, it is feasible to include the brief battery for 
clinical screening of patients with vascular risk factors and 
as a measure of cognition in research studies.
Two recent guideline updates offer contrasting evidence 
of progress. The 2007 guidelines for the management of 
arterial hypertension, created jointly by the European Society 
of Hypertension and the European Society of Cardiology,42 
thoroughly describes the evidence linking hypertension to 
the risk of cognitive impairment, unlike its 2003 predecessor. 
Screening for memory impairment is also suggested, though 
the testing procedures are not described (unlike for renal 
disease and pheochromocytoma). The National Collaborating 
Centre for Chronic Conditions, in updating the British 
Society for Hypertension guidelines, however, removed the 
mention of dementia in its 2006 update of the hypertension 
guideline.34 Instead, it describes cerebrovascular disease 
without reference to cognitive impairment as an adverse 
outcome.
Despite the worldwide burden of cardiovascular risk 
factors and their traditionally understood adverse outcomes, 
under-treatment remains an important problem.56 Whether 
realizing that these also increase the risk of dementia 
will prompt people to modify their lifestyles or to seek 
treatment or physicians to initiate treatment is not clear, but 
on a worldwide basis it might provide enough additional 
motivation to make a difference.
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